1. WHO. 2005. International Health Regulations. World Health Organization
2. Faber JC. 2004. Work of the European Haemovigilance Network (EHN). Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine 11:2-10
3. de Vries RR, Faber JC, Strengers PF, Board of the International Haemovigilance N. 2011. Haemovigilance: an effective tool for improving transfusion practice. Vox Sang 100:60-7
4. Secretariat. 2010. Human Organ and Tissue Transplantation. World Health Organization
5. UN. 2008. Report on the Vienna Forum to Fight Human Trafficking. Proc. The Vienna Forum to Fight Human Trafficking, Vienna, Austria, 2008:20: United Nations
6. Caplan A, Dominguez-Gil, B, Matexanz, R. and Prior, C. 2009. Trafficking in organs, tissues and cells and trafficking in human beings and the replies to the questionnaire for Member States on organ and tissue trafficking (2009), Directorate General of Human Rights and Legal Affairs Council of Europe, Strasbourg, Cedex
7. Chaney A. 2006. Body Brokers. New York, New York: Random House
8. WHO. 2006. Human and Organ Tissue Transplantation. Tranplantation 79:635-7
9. Schulz-Baldes A, Biller-Andorno N, Capron AM. 2007. International perspectives on the ethics and regulation of human cell and tissue transplantation. Bull World Health Organ 85:941-8
10. WHO. 2006. Aide-Memoire - Access to Safe and Effective Cells and Tissues for Transplantation. Geneva, Switzerland: World Health Organization
11. WHO. 2002. Aide-Memoire on Key Safety Requirements For Essential Minimally Processed Human Cells and Tissues For Transplantation. Geneva Switzerland: World Health Organization
12. World Health Assembly. 21 May 2010. Sixty-Third World Health Assembly. WHA63.22. Agenda item 11.21 Human organ and tissue transplantation.
13. Wiersum-Osselton J, Wood, E., Bolton-Maggs, P.H.B. and Schipperus, M.R. 2014. Definitions in haemovigilance: guiding principles and current state of development of international reference definitions. ISBT Sci Ser 9:91-7
14. Honore PA, Wright D, Berwick DM, Clancy CM, Lee P, et al. 2011. Creating a framework for getting quality into the public health system. Health Aff (Millwood) 30:737-45
15. Zou S, Dodd RY, Stramer SL, Strong DM, Tissue Safety Study G. 2004. Probability of viremia with HBV, HCV, HIV, and HTLV among tissue donors in the United States. N Engl J Med 351:751-9
16. Ellingson K, Seem D, Nowicki M, Strong DM, Kuehnert MJ, Organ Procurement Organization Nucleic Acid Testing Yield Project T. 2011. Estimated risk of human immunodeficiency virus and hepatitis C virus infection among potential organ donors from 17 organ procurement organizations in the United States. Am J Transplant 11:1201-8
17. Notify. Exploring Vigilance Notification for Organs, Tissues and Cells. Proc. Organs, Tissues & Cells, Bologna, Italy, 2011, Supplement:1-133: Editrice Compositori
18. Williamson LM, Strong, D.M. 2013. Hemovigilance - Big Brother or Kindly Light. In Quality Management in Transfusion Medicine, ed. CS Sibinga:209-21. Hauppauge, NY, USA: Nova Science. Number of 209-21 pp.
19. Anderlini P, Donato M, Chan KW, Huh YO, Gee AP, et al. 1999. Allogeneic blood progenitor cell collection in normal donors after mobilization with filgrastim: the M.D. Anderson Cancer Center experience. Transfusion 39:555-60
20. American Academy of Pediatrics. Committee on B. 2010. Children as hematopoietic stem cell donors. Pediatrics 125:392-404
21. Mjoen G, Hallan S, Hartmann A, Foss A, Midtvedt K, et al. 2014. Long-term risks for kidney donors. Kidney Int 86:162-7
22. Muzaale AD, Massie AB, Wang MC, Montgomery RA, McBride MA, et al. 2014. Risk of end-stage renal disease following live kidney donation. JAMA 311:579-86
23. Valapour M, J.P. Kahn, R.F. Bailey and A.J. Matas. 2011. Assessing elements of informed consent among living donors. Clinical Transplantation 25:185-90
24. Dew MA, Jacobs CL, Jowsey SG, Hanto R, Miller C, et al. 2007. Guidelines for the psychosocial evaluation of living unrelated kidney donors in the United States. Am J Transplant 7:1047-54
25. ISBT I, AABB. 2014. Standard for surveillance of complications related to blood donation. http://www.isbtweb.org/working-parties/haemovigilance/
26. Eder AF, Dy BA, Kennedy JM, Notari Iv EP, Strupp A, et al. 2008. The American Red Cross donor hemovigilance program: complications of blood donation reported in 2006. Transfusion 48:1809-19
27. Gavillet M, Tissot JD, Canellini G. 2013. Blood donation associated risks: data from a Swiss regional haemovigilance program. Transfus Med 23:269-71
28. Newman BH, Pichette S, Pichette D, Dzaka E. 2003. Adverse effects in blood donors after whole-blood donation: a study of 1000 blood donors interviewed 3 weeks after whole-blood donation. Transfusion 43:598-603
29. Ounnoughene N, Sandid I, Carlier M, Joussemet M, Ferry N. 2013. [The blood donors' haemovigilance in France]. Transfus Clin Biol 20:182-92
30. Sorensen BS, Johnsen SP, Jorgensen J. 2008. Complications related to blood donation: a population-based study. Vox Sang 94:132-7
31. Eder AF, Notari EPt, Dodd RY. 2012. Do reactions after whole blood donation predict syncope on return donation? Transfusion 52:2570-6
32. van Dongen A, Abraham C, Ruiter RA, Veldhuizen IJ. 2013. The influence of adverse reactions, subjective distress, and anxiety on retention of first-time blood donors. Transfusion 53:337-43
33. Veldhuizen I, Atsma F, van Dongen A, de Kort W. 2012. Adverse reactions, psychological factors, and their effect on donor retention in men and women. Transfusion 52:1871-9
34. Wiersum-Osselton JC, Marijt-van der Kreek T, Brand A, Veldhuizen I, van der Bom JG, de Kort W. 2014. Risk factors for complications in donors at first and repeat whole blood donation: a cohort study with assessment of the impact on donor return. Blood Transfus 12 Suppl 1:s28-36
35. Conrad ME, Crosby WH, Jacobs A, Kaltwasser JP, Nusbacher J. 1981. The Hippocratian principle of 'primum nil nocere' demands that the metabolic state of a donor should be normalized prior to a subsequent donation of blood or plasma. How much blood, relative to his body weight, can a donor give over a certain period, without a continuous deviation of iron metabolism in the direction of iron deficiency? Vox Sang 41:336-43
36. Amrein K, Valentin A, Lanzer G, Drexler C. 2012. Adverse events and safety issues in blood donation--a comprehensive review. Blood Rev 26:33-42
37. Laub R, Baurin S, Timmerman D, Branckaert T, Strengers P. 2010. Specific protein content of pools of plasma for fractionation from different sources: impact of frequency of donations. Vox Sang 99:220-31
38. Amrein K, Katschnig C, Sipurzynski S, Stojakovic T, Lanzer G, et al. 2010. Apheresis affects bone and mineral metabolism. Bone 46:789-95
39. Bolan CD, Cecco SA, Yau YY, Wesley RA, Oblitas JM, et al. 2003. Randomized placebo-controlled study of oral calcium carbonate supplementation in plateletpheresis: II. Metabolic effects. Transfusion 43:1414-22
40. Eastlund T, Strong DM. 2004. Infectious disease transmission through tissue transplantation. In Advances in Tissue Banking, ed. GO Phillips, 7:51 - 131. Singapore: World Scientific. Number of 51 - 131 pp.
41. Fishman JA, Grossi PA. 2014. Donor-derived infection--the challenge for transplant safety. Nat Rev Nephrol. 10(11):663-72
42. Ison MG, Nalesnik MA. 2011. An update on donor-derived disease transmission in organ transplantation. Am J Transplant. 11(6):1123-30
43. Perkins HA, Busch MP. 2010. Transfusion-associated infections: 50 years of relentless challenges and remarkable progress. Transfusion 50:2080-99
44. Kuehnert MJ, Roth VR, Haley NR, Gregory KR, Elder KV, et al. 2001. Transfusion-transmitted bacterial infection in the United States, 1998 through 2000. Transfusion 41:1493-9
45. Goldman M, Roy G, Frechette N, Decary F, Massicotte L, Delage G. 1997. Evaluation of donor skin disinfection methods. Transfusion 37:309-12
46. Lee CK, Ho PL, Chan NK, Mak A, Hong J, Lin CK. 2002. Impact of donor arm skin disinfection on the bacterial contamination rate of platelet concentrates. Vox Sang 83:204-8
47. McDonald CP, Lowe P, Roy A, Robbins S, Hartley S, et al. 2001. Evaluation of donor arm disinfection techniques. Vox Sang 80:135-41
48. Chassaigne M, Vassort-Bruneau C, Allouch P, Audurier A, Boulard G, et al. 2001. Reduction of bacterial load by predonation sampling. Transfus Apher Sci 24:253
49. de Korte D, Marcelis JH, Verhoeven AJ, Soeterboek AM. 2002. Diversion of first blood volume results in a reduction of bacterial contamination for whole-blood collections.
Vox Sang 83:13-6
50. Wagner SJ, Robinette D, Friedman LI, Miripol J. 2000. Diversion of initial blood flow to prevent whole-blood contamination by skin surface bacteria: an in vitro model. Transfusion 40:335-8
51. Brecher ME, Hay SN, Rose AD, Rothenberg SJ. 2005. Evaluation of BacT/ALERT plastic culture bottles for use in testing pooled whole blood-derived leukoreduced platelet-rich plasma platelets with a single contaminated unit. Transfusion 45:1512-7
52. Brecher ME, Hay SN, Rothenberg SJ. 2004. Validation of BacT/ALERT plastic culture bottles for use in testing of whole-blood-derived leukoreduced platelet-rich-plasma-derived platelets. Transfusion 44:1174-8
53. McDonald CP, Roy A, Lowe P, Robbins S, Hartley S, Barbara JA. 2001. Evaluation of the BacT/Alert automated blood culture system for detecting bacteria and measuring their growth kinetics in leucodepleted and non-leucodepleted platelet concentrates. Vox Sang 81:154-60
54. FDA. 2014. Fatalities Reported to FDA Following Blood Collection and Transfusion.
55. Stramer SL, Dodd RY, Subgroup AT-TDEID. 2013. Transfusion-transmitted emerging infectious diseases: 30 years of challenges and progress. Transfusion 53:2375-83
56. Stramer SL, Hollinger FB, Katz LM, Kleinman S, Metzel PS, et al. 2009. Emerging infectious disease agents and their potential threat to transfusion safety. Transfusion 49 Suppl 2:1S-29S
57. Delaney M, Wendel S, Bercovitz RS, Cid J, Cohn C, et al. 2016. Transfusion reactions: prevention, diagnosis, and treatment. Lancet
58. Hirayama F. 2013. Current understanding of allergic transfusion reactions: incidence, pathogenesis, laboratory tests, prevention and treatment. Br J Haematol 160:434-44
59. Sanders RP, Maddirala SD, Geiger TL, Pounds S, Sandlund JT, et al. 2005. Premedication with acetaminophen or diphenhydramine for transfusion with leucoreduced blood products in children. Br J Haematol 130:781-7
60. Brubaker DB. 1990. Clinical significance of white cell antibodies in febrile nonhemolytic transfusion reactions. Transfusion 30:733-7
61. Heddle NM, Blajchman MA, Meyer RM, Lipton JH, Walker IR, et al. 2002. A randomized controlled trial comparing the frequency of acute reactions to plasma-removed platelets and prestorage WBC-reduced platelets. Transfusion 42:556-66
62. Cohn CS, Stubbs J, Schwartz J, Francis R, Goss C, et al. 2014. A comparison of adverse reaction rates for PAS C versus plasma platelet units. Transfusion 54:1927-34
63. Janatpour KA, Kalmin ND, Jensen HM, Holland PV. 2008. Clinical outcomes of ABO-incompatible RBC transfusions. Am J Clin Pathol 129:276-81
64. Poole J, Daniels G. 2007. Blood group antibodies and their significance in transfusion medicine. Transfus Med Rev 21:58-71
65. Vlaar AP, Juffermans NP. 2013. Transfusion-related acute lung injury: a clinical review. Lancet 382:984-94
66. Stainsby D, Russell J, Cohen H, Lilleyman J. 2005. Reducing adverse events in blood transfusion. Br J Haematol 131:8-12
67. Stainsby D, Williamson L, Jones H, Cohen H. 2004. 6 Years of shot reporting--its influence on UK blood safety. Transfus Apher Sci 31:123-31
68. Andrzejewski C, Jr., Casey MA, Popovsky MA. 2013. How we view and approach transfusion-associated circulatory overload: pathogenesis, diagnosis, management, mitigation, and prevention. Transfusion 53:3037-47
69. Lieberman L, Maskens C, Cserti-Gazdewich C, Hansen M, Lin Y, et al. 2013. A retrospective review of patient factors, transfusion practices, and outcomes in patients with transfusion-associated circulatory overload. Transfus Med Rev 27:206-12
70. Narick C, Triulzi DJ, Yazer MH. 2012. Transfusion-associated circulatory overload after plasma transfusion. Transfusion 52:160-5
71. Pagano MB, Ness PM, Chajewski OS, King KE, Wu Y, Tobian AA. 2015. Hypotensive transfusion reactions in the era of prestorage leukoreduction. Transfusion
72. Cyr M, Hume HA, Champagne M, Sweeney JD, Blais C, Jr., et al. 1999. Anomaly of the des-Arg9-bradykinin metabolism associated with severe hypotensive reactions during blood transfusions: a preliminary study. Transfusion 39:1084-8
73. Lee AC, Reduque LL, Luban NL, Ness PM, Anton B, Heitmiller ES. 2014. Transfusion-associated hyperkalemic cardiac arrest in pediatric patients receiving massive transfusion. Transfusion 54:244-54
74. Talano JA, Hillery CA, Gottschall JL, Baylerian DM, Scott JP. 2003. Delayed hemolytic transfusion reaction/hyperhemolysis syndrome in children with sickle cell disease. Pediatrics 111:e661-5
75. Waters AH. 1989. Post-transfusion purpura. Blood Rev 3:83-7
76. Menis M, Forshee RA, Anderson SA, McKean S, Gondalia R, et al. 2014. Posttransfusion purpura occurrence and potential risk factors among the inpatient US elderly, as recorded in large Medicare databases during 2011 through 2012. Transfusion
77. Kopolovic I, Ostro J, Tsubota H, Lin Y, Cserti-Gazdewich CM, et al. 2015. A systematic review of transfusion-associated graft-versus-host disease. Blood 126:406-14
78. Ruhl H, Bein G, Sachs UJ. 2009. Transfusion-associated graft-versus-host disease. Transfus Med Rev 23:62-71
79. Andrews NC. 1999. Disorders of iron metabolism. N Engl J Med 341:1986-95
80. Nalesnik MA, Shaprio, R., Ison, M.G. 2013. Malignancy in the Brain Dead Organ donor: Pathophysiology and Management. In The Brain-Dead Organ donor, ed. DaC Novitzky, D.K.C.:177-89. New York, New York: Springer. Number of 177-89 pp.
81. Krance RA, Spruce WE, Forman SJ, Rosen RB, Hecht T, et al. 1982. Human cyclic neutropenia transferred by allogeneic bone marrow grafting. Blood 60:1263-6
82. SOHO. 2011. Guidance on Vigilance & Surveillance in Assisted Reproductive Technologies in the European Union.
http://www.notifylibrary.org/sites/default/files/SOHO V%26S Guidance on V%26S in ART in the European Union.pdf
83. Keim SA, Hogan JS, McNamara KA, Gudimetla V, Dillon CE, et al. 2013. Microbial contamination of human milk purchased via the Internet. Pediatrics 132:e1227-35
84. Keim SA, Kulkarni MM, McNamara K, Geraghty SR, Billock RM, et al. 2015. Cow's Milk Contamination of Human Milk Purchased via the Internet. Pediatrics
85. Carson JL, Guyatt G, Heddle NM, Grossman BJ, Cohn CS, et al. 2016. Clinical Practice Guidelines From the AABB: Red Blood Cell Transfusion Thresholds and Storage. JAMA
86. Piccin A, Cronin M, Brady R, Sweeney J, Marcheselli L, Lawlor E. 2015. Transfusion-associated circulatory overload in Ireland: a review of cases reported to the National Haemovigilance Office 2000 to 2010. Transfusion 55:1223-30
87. Lumadue JA, Boyd JS, Ness PM. 1997. Adherence to a strict specimen-labeling policy decreases the incidence of erroneous blood grouping of blood bank specimens. Transfusion 37:1169-72
88. Dzik WH, Murphy MF, Andreu G, Heddle N, Hogman C, et al. 2003. An international study of the performance of sample collection from patients. Vox Sang 85:40-7
89. Murphy MF, Stearn BE, Dzik WH. 2004. Current performance of patient sample collection in the UK. Transfus Med 14:113-21
90. Linden JV, Wagner K, Voytovich AE, Sheehan J. 2000. Transfusion errors in New York State: an analysis of 10 years' experience. Transfusion 40:1207-13
91. Heddle NM, Fung M, Hervig T, Szczepiorkowski ZM, Torretta L, et al. 2012. Challenges and opportunities to prevent transfusion errors: a Qualitative Evaluation for Safer Transfusion (QUEST). Transfusion 52:1687-95
92. Warren J. 2006. BTS stolen body parts scandal generating gruesome headlines, fears of infection; NY grand jury meeting. Transplant News 16:4
93. Tugwell BD, Patel PR, Williams IT, Hedberg K, Chai F, et al. 2005. Transmission of hepatitis C virus to several organ and tissue recipients from an antibody-negative donor. Ann Intern Med 143:648-54
94. Strong DM, Shinozaki N. 2011. Coding and traceability for cells, tissues and organs for transplantation. Cell Tissue Bank 11:305-23